Release Date: 17 September 2024
Pharma players are enthusiastic in the commercial landscape for next generation multispecific antibody due to its potential to treat many disorders. As there are currently 13 approved products on the market with the overa...
Release Date: 12 September 2024
Bispecific antibody drug conjugates (ADCs) represent a significant advancement in the field of targeted cancer therapy. These innovative agents combine the precision of bispecific antibodies, which can bind to two distinc...
Release Date: 11 September 2024
Targeted therapeutic antibodies have revolutionized cancer treatment, offering precision in targeting cancer cells while sparing healthy tissues. These innovations have emerged from advancements in biotechnology, leading ...
Release Date: 11 September 2024
In the breakneck domain of cancer therapeutics, the arrival of next generation multispecific antibody, including bispecific, trispecific and tetraspecific antibody is making waves on top of catching the eye of investors a...
Release Date: 10 September 2024
The concept of personalized cancer therapy has gained significant traction in recent years, with an increasing focus on tailoring treatments to individual patients based on their unique genetic and molecular profiles. CD1...
Release Date: 10 September 2024
CD137, a co-stimulatory receptor found on T cells, has a profound impact on T cell function, making it a critical target in cancer immunotherapy. T cells are essential in the immune system’s ability to recognize and...
Release Date: 10 September 2024
CD47, often referred to as the "don't eat me" signal, plays a central role in tumor immune escape, a process by which cancer cells evade detection and destruction by the immune system. This transmembrane protein is ubiqui...
Release Date: 09 September 2024
CD137, or 4-1BB, has emerged as a key focus in the field of immunotherapy due to its co-stimulatory function in the activation of T cells. The growing interest in CD137 as a target is driven by its ability to modulate the...
Release Date: 09 September 2024
CD137 agonists are gaining attention as a novel approach to enhancing the immune system’s ability to fight cancer. These agents stimulate CD137, a receptor found on T cells and other immune cells, promoting the acti...
Release Date: 06 September 2024
Bispecific antibody drug conjugates represent a significant advancement in modern cancer therapy, marking a new frontier in targeted treatment. These molecules are engineered to simultaneously bind to two different target...
Release Date: 06 September 2024
The clinical development outlook for bispecific antibody drug conjugates is promising, as these innovative therapies continue to show potential in addressing unmet needs in cancer treatment. The ability of bispecific anti...
Release Date: 04 September 2024
Tetravalent antibodies are an emerging class of therapeutic antibodies that offer enhanced binding capabilities and specificity for precision cancer treatment. With four antigen-binding sites, these antibodies can achieve...
Release Date: 04 September 2024
Trispecific antibodies (TsAbs) represent a cutting-edge advancement in targeted cancer therapy, designed to engage three distinct antigens simultaneously. This complex targeting strategy aims to enhance the precision and ...
Release Date: 04 September 2024
Antibody engineering has revolutionized targeted cancer therapies, enabling the development of highly specific and potent antibodies tailored to attack cancer cells while sparing normal tissues. This innovative field leve...
Release Date: 04 September 2024
Targeted therapeutic antibodies have become a cornerstone in immuno-oncology, offering precise mechanisms to enhance the immune response against cancer cells. These antibodies are designed to recognize and bind specific a...